Can Long-Term Thyroid Cancer Follow-Up Safely Move to Primary Care? Prospective Data Support De-Escalation After Excellent Response

Highlight

In this prospective longitudinal cohort, no biochemical or structural recurrences were observed after a mean 70.3 months of primary care follow-up among patients with differentiated thyroid cancer discharged from specialist care after achieving an excellent response.

Excellent response proved highly stable over time: 94.2% of patients had an excellent response at discharge and 96.1% at reassessment, with no patient deteriorating from excellent response to recurrence.

All abnormal findings at postdischarge reassessment occurred only in patients already classified as having an indeterminate response at discharge, suggesting that the residual uncertainty resides in this subgroup rather than in those with established excellent response.

Although surveillance intensity in primary care was low, with very limited thyroglobulin testing and no routine neck ultrasonography, outcomes remained favorable. However, fear of recurrence remained common and most patients still preferred specialist follow-up.

Background and Clinical Context

Differentiated thyroid cancer, which includes papillary and follicular thyroid carcinoma, is generally associated with excellent long-term survival. For many patients, the central challenge is not mortality reduction but calibrating follow-up intensity to the true risk of recurrence while avoiding unnecessary investigations, hospital visits, cost, and patient anxiety. This is particularly relevant because recurrence risk is heterogeneous and evolves over time rather than remaining fixed at diagnosis.

Dynamic risk stratification has become a major conceptual advance in thyroid cancer management. Instead of relying only on baseline clinicopathologic factors, dynamic risk stratification reassesses recurrence risk according to response to initial therapy. Patients classified as having an excellent response, typically defined by negative imaging and very low or undetectable thyroglobulin with no concerning anti-thyroglobulin antibody trend, have a markedly lower subsequent recurrence risk than would be predicted by baseline staging alone.

American Thyroid Association guidance has increasingly endorsed response-adapted follow-up. However, an important practical question has remained insufficiently answered: once a patient has sustained an excellent response for years, can follow-up be safely de-escalated out of specialist endocrinology or oncology clinics and transitioned to primary care? Retrospective series and guideline logic support this approach, but prospective data on real-world discharge to primary care have been scarce.

The present study by Fernández Velasco and colleagues addresses this gap by prospectively reassessing patients with differentiated thyroid cancer who were discharged to primary care after at least 5 years of specialist follow-up, mostly after achieving an excellent response. The study is clinically important because it tests not simply a biomarker strategy, but a survivorship care model.

Planned Article Structure

This article reviews the study under the following clinically oriented sections: clinical rationale for de-escalation, study design and population, key efficacy and surveillance findings, implications for endocrine and primary care practice, patient-centered considerations, study limitations and generalizability, and the broader place of these findings within current guideline-based care.

Study Design

Design and Setting

This was a longitudinal cohort study with a prospectively conducted postdischarge reassessment. The investigators included 154 patients with differentiated thyroid cancer who had undergone total thyroidectomy, with or without radioiodine ablation, completed at least 5 years of specialist follow-up, and were then discharged to primary care.

Population

The cohort was predominantly composed of patients discharged after an excellent response to therapy. A small subgroup of 9 clinically stable patients was discharged despite a persistent indeterminate response, based on clinician judgment. This is noteworthy because it reflects real-world practice rather than a rigidly idealized cohort.

Baseline recurrence risk according to American Thyroid Association-2025 categories was distributed as follows: low risk in 78 of 154 patients (50.6%), intermediate-low risk in 44 (28.6%), intermediate-high risk in 23 (14.9%), and high risk in 9 (5.8%). Thus, the cohort was not limited exclusively to very low-risk disease, although most patients were on the lower-risk end of the spectrum by baseline assessment.

Dynamic Risk Stratification Time Points

Dynamic risk stratification was evaluated at three predefined points: 6 months after initial therapy, the final specialist visit before discharge, and the postdischarge reassessment performed at least 5 years after transition to primary care. This repeated assessment framework is a strength because it allows evaluation of the stability of response category over a long period.

Endpoints

The main outcomes included recurrence, need for additional interventions, actual follow-up practices in primary care, referrals back to specialist care, and patient-reported outcomes. Patient perspectives were captured using a study-specific 5-point Likert-type questionnaire at reassessment.

Key Results

Response Status Improved Over Time

One of the most important findings is the progressive increase in excellent response classification over the course of follow-up. At 6 months after initial therapy, 118 of 154 patients (76.6%) had an excellent response. By the final predischarge specialist visit, this had risen to 145 of 154 (94.2%). At the postdischarge reassessment, 148 of 154 patients (96.1%) were classified as having an excellent response. This improvement was statistically significant (p < 0.001).

Clinically, this matters because it reinforces a familiar principle in differentiated thyroid cancer: early uncertainty often resolves favorably with time. Small nonspecific biochemical or imaging abnormalities do not necessarily herald recurrence and may normalize or become clinically irrelevant with longitudinal observation.

No Recurrences After Discharge to Primary Care

Over a mean postdischarge follow-up of 70.3 ± 10.6 months, the investigators observed no biochemical or structural recurrences. This is the central result of the study and directly supports the safety of follow-up de-escalation in carefully selected patients.

Importantly, among patients discharged with an excellent response, there was no deterioration at reassessment. All non-excellent response findings identified at the later reassessment occurred only in patients who had already been classified as having an indeterminate response at discharge. In other words, the excellent response category was not only favorable but highly stable.

Indeterminate Response Became Less Common

At the last specialist visit before discharge, 9 of 154 patients (5.8%) had an indeterminate response. By postdischarge reassessment, this number had fallen to 6 of 154 (3.9%). This further supports the view that indeterminate findings often declare themselves as benign over time, though they still represent a distinct group requiring more nuanced clinical judgment.

Additional Interventions During Specialist Follow-Up Were Uncommon

Before discharge, during the specialist follow-up phase, 8 of 154 patients (5.2%) required additional interventions. This low rate suggests that most clinically meaningful events occurred earlier in the disease course, before discharge to primary care. The study therefore captures a survivorship phase in which the residual event rate appears extremely low.

Primary Care Surveillance Was Markedly Less Intensive

The real-world surveillance pattern after discharge is particularly informative. Only 11 of 154 patients (7.1%) underwent thyroglobulin testing in primary care. There was no routine neck ultrasonography, and levothyroxine dosing remained stable. Despite this low-intensity follow-up environment, outcomes remained excellent.

That finding challenges the assumption that frequent specialist-driven biochemical and imaging surveillance is necessary indefinitely after sustained excellent response. It suggests that, in selected patients, long-term care can reasonably focus on thyroid hormone replacement, thyroid-stimulating hormone monitoring, and symptom-triggered reassessment rather than routine intensive cancer surveillance.

Re-Referral to Specialist Care Occurred but Did Not Reflect True Recurrence

Premature referral back to specialist care occurred in 13 of 154 patients (8.4%), but none of these re-referrals were associated with evidence of recurrence. This is clinically significant because it highlights an implementation issue: even if de-escalation is oncologically safe, uncertainty among patients or primary care clinicians may still drive specialist utilization.

Patient-Reported Outcomes Reveal an Important Gap

Despite favorable oncologic outcomes, 66 of 154 patients (42.9%) reported high fear of recurrence, and 141 of 154 (91.6%) stated a preference for specialist follow-up. These findings are highly relevant to survivorship care design. They show that safe de-escalation from a biomedical standpoint does not automatically translate into psychological comfort or perceived acceptability.

Clinical Interpretation

What This Study Adds

The main contribution of this study is prospective evidence supporting a response-adapted transition from specialist care to primary care in differentiated thyroid cancer survivors with sustained excellent response. Current practice has often been guided by expert consensus, retrospective data, and extrapolation from dynamic risk stratification studies. This cohort provides direct real-world evidence that such a model can function safely over approximately 6 years after discharge.

The study also sharpens the clinical distinction between excellent response and indeterminate response. In this cohort, excellent response behaved as a stable remission-like state. By contrast, residual ambiguity was confined to the indeterminate response subgroup, even though that subgroup did not show overt recurrence either.

Why the Findings Are Biologically and Clinically Plausible

Differentiated thyroid cancer is typically indolent, and most recurrences occur within the first years after initial treatment or are heralded by biochemical abnormalities before becoming structurally evident. Patients who remain disease-free for at least 5 years under specialist surveillance and meet excellent response criteria have already passed through the period of greatest clinical uncertainty. The very low event rate seen here is therefore consistent with the known natural history of disease in well-selected survivors.

Implications for Specialist Practice

For endocrinologists and other specialists, these findings support a more deliberate discharge strategy. Patients with at least 5 years of follow-up and sustained excellent response may not require indefinite specialist clinic review. Such de-escalation could reduce outpatient burden and allow tertiary endocrine services to redirect capacity toward patients with persistent structural disease, biochemical persistence, complex hormone management, or treatment-related complications.

Implications for Primary Care

For family physicians and general internists, the study suggests that long-term management of these survivors can be practical and focused. The core tasks are likely to include levothyroxine management, periodic TSH monitoring, attention to symptoms, and awareness of triggers for re-referral. Routine neck ultrasound and serial thyroglobulin testing may not be necessary in all patients with long-standing excellent response, although local protocols and prior disease features should guide practice.

At the same time, the frequency of nonrecurrence-related re-referral indicates a need for clear shared-care pathways. Primary care clinicians may benefit from concise discharge summaries specifying recurrence history, response status, target TSH range, recommended laboratory schedule, and criteria for specialist re-engagement.

Expert Commentary and Context Within Guidelines

The findings align closely with the logic of the 2015 American Thyroid Association management guidelines, which emphasize ongoing risk estimation based on response to therapy rather than diagnosis-stage variables alone. These guidelines recognize that an excellent response substantially reduces the need for intensive follow-up and TSH suppression. The present study extends that principle from theoretical risk adaptation to actual care relocation.

More recent European and international discussions around thyroid cancer survivorship have similarly emphasized reducing overtreatment and avoiding excess surveillance in low-risk patients. In that context, this study is timely. It supports a model in which differentiated thyroid cancer follow-up increasingly resembles chronic disease management rather than lifelong oncologic surveillance for everyone.

Still, caution is warranted. The study should not be interpreted as support for indiscriminate discharge of all thyroid cancer survivors. The favorable results are tied to a highly selected population: total thyroidectomy-treated patients who completed at least 5 years of specialist follow-up and largely had excellent response at discharge. These data should therefore reinforce response-adapted care, not replace it.

Limitations

Several limitations deserve attention. First, this was a single-cohort observational study without a contemporaneous specialist-follow-up control group. The absence of recurrence is reassuring, but comparative effectiveness cannot be directly quantified. Second, the sample size was modest, particularly for higher-risk baseline categories and for the subgroup discharged with indeterminate response. Rare late recurrences therefore cannot be excluded.

Third, the cohort was restricted to patients treated with total thyroidectomy, with or without radioiodine ablation, which may limit generalizability to contemporary patients treated with lobectomy alone or to those managed without radioiodine under more conservative protocols. Fourth, details of thyroglobulin assay harmonization, anti-thyroglobulin antibody dynamics, and imaging thresholds were not central to the abstract and may affect interpretation across settings.

Finally, the high prevalence of fear of recurrence and overwhelming preference for specialist follow-up indicate that implementation barriers may be psychological and organizational rather than oncologic. Safe de-escalation is not simply a question of biology; it also requires patient education, communication, and confidence in primary care systems.

Practical Takeaways for Clinicians

For patients with differentiated thyroid cancer who have undergone total thyroidectomy, completed at least 5 years of specialist follow-up, and achieved a sustained excellent response, discharge to primary care appears reasonable and likely safe.

Excellent response should be treated as a robust long-term prognostic state. In this study, no patient with excellent response experienced deterioration at late reassessment.

Patients with indeterminate response are a distinct group. Although outcomes remained favorable, residual uncertainty clustered entirely in this subgroup, suggesting that discharge decisions should be more individualized.

Primary care follow-up can be low intensity, but it should not be unstructured. Written surveillance plans and explicit re-referral criteria are likely essential.

Psychological survivorship needs remain substantial. Fear of recurrence may persist even when objective risk is extremely low, so reassurance should be evidence-based, repeated, and accompanied by clear care pathways.

Conclusion

This prospective evaluation provides compelling support for response-adapted de-escalation of long-term follow-up in differentiated thyroid cancer. Among patients who completed at least 5 years of specialist surveillance and achieved an excellent response, transition to primary care was associated with no biochemical or structural recurrences over nearly 6 additional years of follow-up, despite minimal biochemical testing and no routine imaging. The data suggest that excellent response is not simply a favorable short-term category but a durable clinical state that can justify a shift from specialist cancer surveillance to primary care management centered on levothyroxine replacement and TSH monitoring.

The study also exposes the next challenge for the field: implementation. Even when recurrence risk is very low, patients may still fear recurrence and prefer specialist oversight. Future research should therefore move beyond recurrence endpoints alone and test structured shared-care models, patient education strategies, and supportive interventions that make de-escalation both clinically safe and psychologically acceptable.

Funding and ClinicalTrials.gov

Funding information was not provided in the source abstract. A ClinicalTrials.gov registration number was not reported in the source abstract.

References

1. Fernández Velasco P, Torres B, Estévez Asensio L, Cocho Cuesta A, Nieto de la Marca MO, Ortolá Buigues A, Gómez Hoyos E, de Luis Román D, Díaz Soto G. Prospective Evaluation of Follow-Up De-Escalation to Primary Care in Differentiated Thyroid Cancer with Excellent Response to Therapy. Thyroid. 2026 May 25:10507256261454209. PMID: 42184216.

2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. PMID: 26462967.

3. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A, Sherman SI. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new ATA staging system. Thyroid. 2010;20(12):1341-1349. PMID: 21034228.

4. Momesso DP, Vaisman F, Yang SP, Bulzico DA, Corbo R, Vaisman M, Tuttle RM. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab. 2016;101(7):2692-2700. PMID: 27148975.

5. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, McCaffrey J, Moley JF, Pacini F, Shah JP, Sherman SI, Wong RJ, Wirth LJ, Hoffmann KG. Thyroid carcinoma, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(8):925-951. PMID: 35908225.